‘Watch and wait’ after chemoradiotherapy for rectal cancer
ANZ Journal of Surgery2018Vol. 88(9), pp. 836–841
Citations Over Time
Abstract
Surgery remains the cornerstone of rectal cancer treatment. However, there is significant morbidity and mortality associated with pelvic surgery, and the past decade has illustrated that a cohort of rectal cancer patients sustain a remission of local disease with chemoradiation alone. Thus, questions remain regarding the optimal management for rectal cancer; namely, accurately identifying patients who have a complete pathologic response and determining the oncologic safety of the observational approach for this patient group. This review aims to summarize the current evidence to provide an overview to the 'watch and wait' approach in rectal cancer patients with a complete response to neoadjuvant chemoradiation therapy.
Related Papers
- → Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015(2019)217 cited
- → Watchful waiting for prostate cancer: a review article(2006)29 cited
- → Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?(2007)7 cited
- → Is Watchful Waiting Necommendable in Patients with Low-Grade, Organ-Confined Cancer of the Prostate? “Watchful Waiting” or “Watchful Progression”?(1999)
- → MP-02.15 Outcomes and Tumour Growth Rate of Renal Masses Are Dependent on Size at Presentation in a Watchful Waiting Cohort(2011)